article thumbnail

Top pharma and biotech conferences 2025

PharmaVoice

Mark your calendars for the most important industry conferences in 2025.

253
253
article thumbnail

STAT+: Medicare Advantage market expected to grow in 2025, despite big changes from insurers

STAT

That’s why the federal government expects enrollment in the $500 billion Medicare Advantage program to grow once again in 2025 — a stark contrast from insurers’ cries that modest payment reforms would damage them and seniors’ options.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025

STAT

billion in 2025, a spokesperson for the Centers for Medicare and Medicaid Services confirmed to STAT. Medicare’s actuaries expect the drug Leqembi , made by the Japanese drugmaker Eisai and sold in partnership with Biogen, to cost the traditional Medicare program around $550 million in 2024, and the entire Medicare program $3.5

article thumbnail

NAPLEX Changes in 2025: What Pharmacists Need to Know

Med Ed 101

NABP recently released information on what to expect for those taking the NAPLEX exam on or after May 1st, 2025. There are some significant changes to the content outline and I outline those changes in the Youtube […] The post NAPLEX Changes in 2025: What Pharmacists Need to Know appeared first on Med Ed 101.

105
105
article thumbnail

STAT+: Biden administration sticks with slight cuts to 2025 Medicare Advantage payments

STAT

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities.

Hospitals 363
article thumbnail

GEP Outlook 2025

Pharma and Life Sciences Blog

GEP Outlook 2025 priyanka.katke… Thu, 11/14/2024 - 14:45 Drive Procurement and Supply Chain Success in 2025 For years, you and your team have fought an uphill battle. Supply disruptions. Cost pressures. ESG compliance. Geopolitical tensions. You name it, and you’ve had to navigate it.

52
article thumbnail

The top biopharma conferences in 2025

BioPharma Dive

Here’s a list of conferences to watch in 2025. Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress.

118
118